Drug intelligence / Profile preview

recombinant respiratory syncytial virus vaccine (CHO)

Development stage: Unknown
Lead developer: Grand Theravac Life Science Nanjing
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Recombinant respiratory syncytial virus vaccine (CHO) is a protein subunit vaccine developed by Grand Theravac Life Science Nanjing for the prevention of respiratory syncytial virus (RSV) infection. The vaccine is produced using a Chinese Hamster Ovary (CHO) cell expression system and is designed to induce protective immune responses against RSV antigens. The candidate received Investigational New Drug (IND) approval from Chinese regulatory authorities on December 22, 2025, and is currently in Phase 1 clinical development.

Other names: Recombinant RSV Vaccine (CHO)Recombinant RSV protein vaccine (CHO-produced)recombinant respiratory syncytial virus vaccine (Chinese hamster ovary)

Beyond the preview

Go deeper on recombinant respiratory syncytial virus vaccine (CHO).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant respiratory syncytial virus vaccine (CHO).

Explore the full profile